INFI News and Press, Infinity Pharmaceuticals Inc. From 03/22/22

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, March 29 th , 2022 at 4:30 p.m. ET to report its fin...

Infinity Pharmaceuticals, Inc . (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-...

Virtual fireside chat scheduled for Jan 27 th at 10:30 am ET Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that it...

Infinity Pharmaceuticals, Inc . (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that Adelene Perkins, Chief Executive Officer, will give a corporat...

- MARIO-4 registration study in frontline metastatic triple negative breast cancer to be initiated by year end 2022 - - MARIO-P platform study in multiple solid tumors to be initiated on a rolling basis in 3Q 2022 - Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) a...

If you’re looking to make money in the stock market before the new year, you’ve got your work cut out for you. With broader indexes swaying, is there any place to find opportunity? In my opinion, if you understand how to handle a bit more risk and have a keen understanding of ...

Intercontinental Exchange will add 138 securities to the ICE Biotechnology index and delete 26 as part of the annual reconstitution, effective prior to market open on December 20. Notable additions: Aurinia Pharmaceuticals (NASDAQ:AUPH), Anavex Life Sciences (NASDAQ:AVXL), Sesen Bio...

Infinity Pharmaceuticals (NASDAQ:INFI) trades 1.3% down premarket has been selected for addition to the NASDAQ Biotechnology Index, effective Dec.20 as of market open. To be selected for addition to the index, a company must have a minimum market capitalization of $200M demonst...

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced it has been selected for addition to the NASDAQ Biotechnology Index (...

Infinity is being highlighted as part of B. Riley’s Fall 2021 Growth Biotech “Best Ideas” research series including an interactive discussion with KOL, Hatem Soliman, MD Virtual fireside chat scheduled for Tuesday, December 14 th @ 2:30pm ET ...